Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

曲美替尼 医学 达布拉芬尼 内科学 人口 不利影响 肿瘤科 实体瘤疗效评价标准 MEK抑制剂 肺癌 临床研究阶段 癌症 胃肠病学 临床终点 临床试验 威罗菲尼 MAPK/ERK通路 转移性黑色素瘤 激酶 环境卫生 细胞生物学 生物
作者
David Planchard,Egbert Frederik Smit,Harry J.M. Groen,Julien Mazières,Benjamin Besse,Åslaug Helland,Vanessa Giannone,Anthony Michael D'amelio,Pingkuan Zhang,Bijoyesh Mookerjee,Bruce Evan Johnson
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (10): 1307-1316 被引量:1423
标识
DOI:10.1016/s1470-2045(17)30679-4
摘要

Background BRAFV600E mutation occurs in 1–2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial antitumour activity in patients with previously treated BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of dabrafenib plus trametinib treatment in previously untreated patients with BRAFV600E-mutant metastatic NSCLC. Methods In this phase 2, sequentially enrolled, multicohort, multicentre, non-randomised, open-label study, adults (≥18 years of age) with previously untreated metastatic BRAFV600E-mutant NSCLC were enrolled into cohort C from 19 centres in eight countries within North America, Europe, and Asia. Patients received oral dabrafenib 150 mg twice per day plus oral trametinib 2 mg once per day until disease progression, unacceptable adverse events, consent withdrawal, or death. The primary endpoint was investigator-assessed overall response, defined as the percentage of patients who achieved a confirmed complete response or partial response per Response Evaluation Criteria In Solid Tumors version 1.1. The primary and safety analyses were by intention to treat in the protocol-defined population (previously untreated patients). The study is ongoing, but no longer recruiting patients. This trial is registered with ClinicalTrials.gov, number NCT01336634. Findings Between April 16, 2014, and Dec 28, 2015, 36 patients were enrolled and treated with first-line dabrafenib plus trametinib. Median follow-up was 15·9 months (IQR 7·8–22·0) at the data cutoff (April 28, 2017). The proportion of patients with investigator-assessed confirmed overall response was 23 (64%, 95% CI 46–79), with two (6%) patients achieving a complete response and 21 (58%) a partial response. All patients had one or more adverse event of any grade, and 25 (69%) had one or more grade 3 or 4 event. The most common (occurring in more than two patients) grade 3 or 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase (four [11%]), hypertension (four [11%]), and vomiting (three [8%]). Serious adverse events occurring in more than two patients included alanine aminotransferase increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increase (three [8%]), and ejection fraction decrease (three [8%]). One fatal serious adverse event deemed unrelated to study treatment was reported (cardiorespiratory arrest). Interpretation Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC. Funding Novartis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lemon发布了新的文献求助10
1秒前
3秒前
yang发布了新的文献求助10
3秒前
3秒前
常常嘻嘻发布了新的文献求助10
3秒前
可爱的函函的应助被瓶子君152采纳,获得10
3秒前
今后的应助被跳跃靖采纳,获得10
4秒前
4秒前
马剃天爱星完成签到,获得积分10
5秒前
Ava的应助被WX采纳,获得10
5秒前
5秒前
yy发布了新的文献求助30
5秒前
郭娅楠发布了新的文献求助10
7秒前
7秒前
jimgyi完成签到,获得积分10
7秒前
花花牛不是牛完成签到,获得积分20
7秒前
CipherSage的应助被dan采纳,获得10
8秒前
8秒前
庸人自扰完成签到,获得积分10
8秒前
8秒前
上官若男的应助被Lu采纳,获得10
9秒前
369ninja发布了新的文献求助10
9秒前
007完成签到,获得积分10
9秒前
晚霞跌落星河的应助被tang采纳,获得100
10秒前
yang发布了新的文献求助10
11秒前
12秒前
12秒前
11111发布了新的文献求助10
13秒前
ihuu发布了新的文献求助10
13秒前
柏林发布了新的文献求助10
13秒前
Lemon发布了新的文献求助10
14秒前
14秒前
15秒前
李思超发布了新的文献求助220
15秒前
乌贼爱吃完成签到,获得积分10
15秒前
17秒前
17秒前
001完成签到,获得积分10
17秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817